Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
99 hedge funds and large institutions have $449M invested in Stemline Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 20 reducing their positions, and 18 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 20
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1% more capital invested
Capital invested by funds: $445M → $449M (+$3.76M)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
1% less funds holding
Funds holding: 100 → 99 (-1)
50% less call options, than puts
Call options by funds: $314K | Put options by funds: $631K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$9.11M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.08M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$3.72M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.43M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$12.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.8M |
| 3 |
Millennium Management
New York
|
-$5.41M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$3.78M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$2.82M |
STML Hedge Fund Activity: Q4 2019 in Review
99 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2019, worth a combined $449M — up 0.84% from $445M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of STML and 17 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 46 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $9.11M. The largest seller was HealthCor Management, exiting entirely with an estimated $12.9M sold.
- 99 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2019, down from 100 in Q3 2019.
- Funds reported $449M of Stemline Therapeutics, Inc. stock for Q4 2019, up 0.84% quarter-over-quarter.
- 17 funds opened new Stemline Therapeutics, Inc. positions in Q4 2019 and 18 closed out, a net change of -1 holder.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2019 was Rubric Capital Management (New York), an estimated $9.11M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2019 was HealthCor Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q4 2019.